JP7653362B2 - 二環式化合物 - Google Patents
二環式化合物 Download PDFInfo
- Publication number
- JP7653362B2 JP7653362B2 JP2021561601A JP2021561601A JP7653362B2 JP 7653362 B2 JP7653362 B2 JP 7653362B2 JP 2021561601 A JP2021561601 A JP 2021561601A JP 2021561601 A JP2021561601 A JP 2021561601A JP 7653362 B2 JP7653362 B2 JP 7653362B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- cancer
- pharma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/25—Aminoacetonitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C261/00—Derivatives of cyanic acid
- C07C261/04—Cyanamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Epoxy Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962834671P | 2019-04-16 | 2019-04-16 | |
| US62/834,671 | 2019-04-16 | ||
| PCT/US2020/028363 WO2020214734A1 (en) | 2019-04-16 | 2020-04-15 | Bicyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529642A JP2022529642A (ja) | 2022-06-23 |
| JP2022529642A5 JP2022529642A5 (cg-RX-API-DMAC7.html) | 2023-04-19 |
| JP7653362B2 true JP7653362B2 (ja) | 2025-03-28 |
Family
ID=72838396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561601A Active JP7653362B2 (ja) | 2019-04-16 | 2020-04-15 | 二環式化合物 |
Country Status (18)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3877356A4 (en) | 2018-11-09 | 2022-06-22 | Vivace Therapeutics, Inc. | BICYCLIC LINKS |
| AU2020257207B2 (en) | 2019-04-16 | 2026-06-04 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| CN115279368B (zh) * | 2019-11-20 | 2024-05-24 | 维瓦斯治疗公司 | 杂芳基化合物 |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| BR112023014751A2 (pt) | 2021-01-25 | 2023-10-03 | Ikena Oncology Inc | Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão |
| EP4284380A4 (en) * | 2021-01-26 | 2024-12-18 | The United States Government as represented by the Department of Veterans Affairs | COMPOSITIONS AND METHODS FOR INHIBITING YAP |
| US12655150B2 (en) | 2021-03-26 | 2026-06-16 | Cedilla Therapeutics, Inc. | TEAD inhibitors and uses thereof |
| AU2022258968A1 (en) | 2021-04-16 | 2023-10-19 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| CN117956996A (zh) * | 2021-05-11 | 2024-04-30 | Opna 生物公司 | 用于yap/tead调节的化合物和方法及其适应证 |
| AR125921A1 (es) * | 2021-05-19 | 2023-08-23 | Genentech Inc | Terapia de combinación |
| WO2022272036A1 (en) * | 2021-06-25 | 2022-12-29 | Cedilla Therapeutics, Inc. | Tead inhibitors and uses thereof |
| WO2023057371A1 (en) | 2021-10-04 | 2023-04-13 | Basilea Pharmaceutica International Ag, Allschwil | 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer |
| WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| AU2023211607A1 (en) * | 2022-01-28 | 2024-08-22 | Opna Bio SA | Compounds and methods for yap/tead modulation and indications therefor |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| JP2025513725A (ja) * | 2022-03-22 | 2025-04-30 | スポロス バイオディスカバリー,インク. | Tead阻害剤および使用方法 |
| CN119768393A (zh) | 2022-05-25 | 2025-04-04 | 医肯纳肿瘤学公司 | Mek抑制剂和其用途 |
| IL318203A (en) * | 2022-07-12 | 2025-03-01 | Adama Makhteshim Ltd | Process for preparing modified benzamides |
| CN119968359A (zh) | 2022-09-29 | 2025-05-09 | 英矽智能科技知识产权有限公司 | Tead抑制剂及其使用方法 |
| WO2024092116A1 (en) | 2022-10-26 | 2024-05-02 | Ikena Oncology, Inc. | Combination of tead inhibitors and egfr inhibitors and uses thereof |
| WO2024088399A1 (zh) * | 2022-10-27 | 2024-05-02 | 勤浩医药(苏州)有限公司 | 含磷化合物、药物组合物及其应用 |
| WO2024105610A1 (en) | 2022-11-18 | 2024-05-23 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| WO2024173761A1 (en) | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
| CN120659608A (zh) | 2023-02-23 | 2025-09-16 | 诺华股份有限公司 | 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合 |
| EP4669319A1 (en) | 2023-02-23 | 2025-12-31 | Novartis AG | TEAD AND HER2 INHIBITOR COMBINATIONS FOR CANCER TREATMENT |
| JP2026513205A (ja) * | 2023-03-27 | 2026-04-23 | ビバーチェ セラピューティクス,インク. | Hippo-yap経路モジュレーターの合成およびその多形体 |
| WO2024216121A1 (en) * | 2023-04-14 | 2024-10-17 | Vivace Therapeutics, Inc. | Pharmaceutical formulations and dosing schedules of a hippo-yap pathway modulator |
| TW202448857A (zh) * | 2023-05-12 | 2024-12-16 | 大陸商正大天晴藥業集團股份有限公司 | 含有芳香二並環的化合物 |
| JP2026519523A (ja) * | 2023-05-24 | 2026-06-16 | ビアクティカ セラピューティクス エービー | Teadへの結合剤としての芳香族アミドおよびそのコンジュゲート |
| WO2025034563A1 (en) * | 2023-08-04 | 2025-02-13 | Vivace Therapeutics, Inc. | Compounds and methods for treating cancer |
| WO2025101655A1 (en) * | 2023-11-08 | 2025-05-15 | Vivace Therapeutics, Inc. | Compounds for modulating yap-tead/hippo pathway |
| WO2025122956A1 (en) * | 2023-12-08 | 2025-06-12 | Vivace Therapeutics, Inc. | Combination therapy |
| TW202547484A (zh) | 2024-04-10 | 2025-12-16 | 瑞士商諾華公司 | 藥物組合及其用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013188138A1 (en) | 2012-06-11 | 2013-12-19 | The Regents Of The University Of California | Inhibitors of hippo-yap signaling pathway |
| WO2016153948A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders |
| WO2017058716A1 (en) | 2015-09-28 | 2017-04-06 | Vivace Therapeutics, Inc. | Tricyclic compounds |
| WO2018028591A1 (zh) | 2016-08-09 | 2018-02-15 | 殷建明 | 一种喹啉衍生物及其用途 |
| JP2018534326A (ja) | 2015-11-20 | 2018-11-22 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | Ror−ガンマのモジュレーター |
| WO2019148044A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JP2001511813A (ja) | 1997-02-18 | 2001-08-14 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | Crfレセプターアンタゴニストおよびそれらに関連する方法 |
| EP1042295B1 (en) | 1997-12-22 | 2005-09-07 | Pharmacia & Upjohn Company LLC | 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents |
| IT1303123B1 (it) | 1998-10-13 | 2000-10-30 | Rotta Research Lab | Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
| US7067532B2 (en) | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| US7544699B2 (en) | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| JP4847459B2 (ja) * | 2005-01-25 | 2011-12-28 | 田辺三菱製薬株式会社 | ノルバリン誘導体及びその製造方法 |
| CN102351791B (zh) | 2006-01-27 | 2014-10-29 | 菲布罗根有限公司 | 使低氧诱导因子(hif)稳定的氰基异喹啉化合物 |
| US20070259960A1 (en) | 2006-02-16 | 2007-11-08 | Fibrogen, Inc. | Compounds and methods for treatment of stroke |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2008023157A1 (en) | 2006-08-21 | 2008-02-28 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as m3-receptor modulators |
| AR065093A1 (es) | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| EP2481735A1 (en) | 2007-05-09 | 2012-08-01 | Pfizer Inc. | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials |
| ES2614269T3 (es) | 2007-08-03 | 2017-05-30 | Biotron Limited | Procedimientos y composiciones antivíricas frente a la hepatitis C |
| BRPI0819453A2 (pt) | 2007-11-28 | 2014-10-07 | Dana Farber Cancer Inst Inc | Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit |
| EP2231156A1 (en) | 2007-12-07 | 2010-09-29 | Fibrogen, Inc. | Methods for increasing white blood cells |
| BRPI1013988A2 (pt) | 2009-04-06 | 2016-04-05 | Daiichi Sankyo Co Ltd | composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo |
| AU2010239188B2 (en) | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| KR20130140020A (ko) | 2010-10-22 | 2013-12-23 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 억제제로서의 아미노-피롤리딘-아제티딘 다이아미드 |
| CA2743391A1 (en) | 2011-05-27 | 2012-11-27 | Queen's University At Kingston | Compounds and methods for catalytic directed ortho substitution of aromatic amides and esters |
| US9278960B2 (en) | 2011-11-03 | 2016-03-08 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use |
| WO2013086229A1 (en) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| SG11201500234YA (en) | 2012-07-16 | 2015-02-27 | Fibrogen Inc | Process for making isoquinoline compounds |
| JP6113354B2 (ja) | 2013-05-03 | 2017-04-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 神経新生刺激イソキノリン誘導体 |
| US20140336182A1 (en) * | 2013-05-13 | 2014-11-13 | Amgen Inc. | Aurora Kinase Modulators and Method of Use |
| US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| MX2016010056A (es) * | 2014-02-06 | 2016-11-15 | Abbvie Inc | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. |
| JP6377245B2 (ja) | 2014-03-24 | 2018-08-22 | グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド | Smo阻害剤としてのキノリン誘導体 |
| EP3247705B1 (en) | 2015-01-20 | 2019-11-20 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof as nampt inhibitors |
| EP3156404A1 (en) | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| US10576085B2 (en) * | 2016-04-01 | 2020-03-03 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| US11186554B2 (en) * | 2017-05-03 | 2021-11-30 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| WO2019040389A1 (en) | 2017-08-21 | 2019-02-28 | Palmese Giuseppe R | RENEWABLE FURANE AMINE CURING AGENTS FOR THERMOSETTING EPOXY PLASTIC |
| CN112236172A (zh) | 2018-01-30 | 2021-01-15 | 福宏治疗公司 | 用于治疗病症的方法和化合物 |
| EP3877356A4 (en) | 2018-11-09 | 2022-06-22 | Vivace Therapeutics, Inc. | BICYCLIC LINKS |
| AU2020257207B2 (en) | 2019-04-16 | 2026-06-04 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| US20240025913A1 (en) | 2020-10-21 | 2024-01-25 | Vivace Therapeutics, Inc. | Tertiary carboxamide compounds |
-
2020
- 2020-04-15 AU AU2020257207A patent/AU2020257207B2/en active Active
- 2020-04-15 FI FIEP20791635.4T patent/FI3956033T3/fi active
- 2020-04-15 KR KR1020217036838A patent/KR102909464B1/ko active Active
- 2020-04-15 IL IL287222A patent/IL287222B2/en unknown
- 2020-04-15 DK DK20791635.4T patent/DK3956033T3/da active
- 2020-04-15 MX MX2021012638A patent/MX2021012638A/es unknown
- 2020-04-15 BR BR112021020629A patent/BR112021020629A2/pt unknown
- 2020-04-15 US US16/849,728 patent/US11420935B2/en active Active
- 2020-04-15 PL PL20791635.4T patent/PL3956033T3/pl unknown
- 2020-04-15 EP EP20791635.4A patent/EP3956033B1/en active Active
- 2020-04-15 WO PCT/US2020/028363 patent/WO2020214734A1/en not_active Ceased
- 2020-04-15 CN CN202080044416.7A patent/CN114072207B/zh active Active
- 2020-04-15 TW TW109112690A patent/TWI849107B/zh active
- 2020-04-15 JP JP2021561601A patent/JP7653362B2/ja active Active
- 2020-04-15 CA CA3137025A patent/CA3137025A1/en active Pending
- 2020-04-15 SG SG11202111404XA patent/SG11202111404XA/en unknown
- 2020-04-15 HU HUE20791635A patent/HUE070525T2/hu unknown
- 2020-04-15 ES ES20791635T patent/ES3014444T3/es active Active
-
2022
- 2022-05-24 US US17/752,649 patent/US12103902B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013188138A1 (en) | 2012-06-11 | 2013-12-19 | The Regents Of The University Of California | Inhibitors of hippo-yap signaling pathway |
| WO2016153948A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders |
| WO2017058716A1 (en) | 2015-09-28 | 2017-04-06 | Vivace Therapeutics, Inc. | Tricyclic compounds |
| JP2018534326A (ja) | 2015-11-20 | 2018-11-22 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | Ror−ガンマのモジュレーター |
| WO2018028591A1 (zh) | 2016-08-09 | 2018-02-15 | 殷建明 | 一种喹啉衍生物及其用途 |
| WO2019148044A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE PubChem,2012年11月30日,https://pubchem.ncbi.nlm.nih.gov/compound/68784747,Compound CID 68784747 |
| DATABASE PubChem,2012年12月01日,https://pubchem.ncbi.nlm.nih.gov/compound/70167127,Compound CID 70167127 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL287222B1 (en) | 2024-12-01 |
| PL3956033T3 (pl) | 2025-06-09 |
| DK3956033T3 (da) | 2025-03-03 |
| BR112021020629A2 (pt) | 2022-01-25 |
| WO2020214734A1 (en) | 2020-10-22 |
| US11420935B2 (en) | 2022-08-23 |
| EP3956033A1 (en) | 2022-02-23 |
| CN114072207A (zh) | 2022-02-18 |
| KR20220016456A (ko) | 2022-02-09 |
| IL287222B2 (en) | 2025-04-01 |
| JP2022529642A (ja) | 2022-06-23 |
| US20220298102A1 (en) | 2022-09-22 |
| EP3956033B1 (en) | 2024-12-11 |
| US12103902B2 (en) | 2024-10-01 |
| AU2020257207B2 (en) | 2026-06-04 |
| US20200347009A1 (en) | 2020-11-05 |
| CN114072207B (zh) | 2024-03-29 |
| CA3137025A1 (en) | 2020-10-22 |
| HUE070525T2 (hu) | 2025-06-28 |
| IL287222A (en) | 2021-12-01 |
| KR102909464B1 (ko) | 2026-01-09 |
| SG11202111404XA (en) | 2021-11-29 |
| AU2020257207A1 (en) | 2021-11-25 |
| TW202104189A (zh) | 2021-02-01 |
| FI3956033T3 (fi) | 2025-03-17 |
| TWI849107B (zh) | 2024-07-21 |
| EP3956033A4 (en) | 2023-01-11 |
| MX2021012638A (es) | 2022-01-04 |
| ES3014444T3 (en) | 2025-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12103902B2 (en) | Bicyclic compounds | |
| JP7482861B2 (ja) | 二環式化合物 | |
| JP7245229B2 (ja) | ベンゾスルホニル化合物 | |
| US11524943B1 (en) | Benzocarbonyl compounds | |
| US20210238154A1 (en) | Oxadiazole compounds | |
| WO2021102204A1 (en) | Heteroaryl compounds | |
| WO2022087008A1 (en) | Tertiary carboxamide compounds | |
| WO2025122956A1 (en) | Combination therapy | |
| WO2023146513A1 (en) | Compounds and methods of use thereof | |
| WO2025034563A1 (en) | Compounds and methods for treating cancer | |
| EA047446B1 (ru) | Бициклические соединения | |
| HK40068715A (en) | Bicyclic compounds | |
| HK40068715B (en) | Bicyclic compounds | |
| EA046394B1 (ru) | Бициклические соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220127 |
|
| RD12 | Notification of acceptance of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7432 Effective date: 20221212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230410 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230410 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240321 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240321 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240618 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240909 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250210 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250305 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250317 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7653362 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |